Offering End-to-End Solutions
A global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics.
Technology platforms that span the entire drug discovery to manufacturing spectrum.
A WuXi Biologics subsidiary, greatly simplifies bioconjugate development and manufacturing.
Unparalleled capacities and expertise for the discovery, development and cGMP manufacture of biologics from concept to commercialization.
Providing extensive expertise and high-quality biosafety testing under EMA, ISO (CNAS) and CMA certified laboratories.
E. coli and yeast based expression systems, process development and cGMP manufacturing platform
World-class quality systems approved by the U.S. FDA, EMA and NMPA.
Viral vector based vaccine and therapeutic virus development and cGMP manufacturing platform.
Total estimated capacity for biopharmaceutical production in China, Ireland, the U.S., Germany and Singapore to exceed 580,000 liters by 2026.